

Wim van den Brink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1581475/publications.pdf>

Version: 2024-02-01

176
papers

7,627
citations

66234

42
h-index

66788

78
g-index

183
all docs

183
docs citations

183
times ranked

8681
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review. <i>Current Neuropharmacology</i> , 2022, 20, 809-819.	1.4	5
2	Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 83-94.	1.0	12
3	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	1.6	75
4	Recreational N ₂ O use: just laughing or really bad news?. <i>Addiction</i> , 2022, 117, 268-269.	1.7	8
5	Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. <i>Psychopharmacology</i> , 2022, 239, 15-33.	1.5	45
6	Self-Medication of ADHD Symptoms: Does Caffeine Have a Role?. <i>Frontiers in Psychiatry</i> , 2022, 13, 813545.	1.3	3
7	Monitoring Opioids in Europe: The Need for Shared Definitions and Measuring Drivers of Opioid Use and Related Harms. <i>European Addiction Research</i> , 2022, 28, 231-240.	1.3	12
8	What lessons from Europe's experience could be applied in the United States in response to the opioid addiction and overdose crisis?. <i>Addiction</i> , 2022, 117, 1197-1198.	1.7	6
9	Nitrous oxide-induced reproductive risks: Should recreational nitrous oxide users worry?. <i>Journal of Psychopharmacology</i> , 2022, 36, 951-955.	2.0	4
10	Increasing recreational nitrous oxide use: Should we worry? A narrative review. <i>Journal of Psychopharmacology</i> , 2022, 36, 943-950.	2.0	14
11	Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2022, 36, 1136-1145.	2.0	5
12	Use characteristics and harm potential of ecstasy in The Netherlands. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 107-117.	0.8	3
13	Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. <i>British Journal of Psychiatry</i> , 2021, 218, 88-94.	1.7	54
14	Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. <i>European Psychiatry</i> , 2021, 64, e47.	0.1	47
15	Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. <i>Journal of Psychopharmacology</i> , 2021, 35, 537-546.	2.0	3
16	Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 659-670.	1.0	5
17	Is Europe Facing an Emerging Opioid Crisis Comparable to the U.S.?. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 42-51.	1.0	43
18	Genomic relationships across psychiatric disorders including substance use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108535.	1.6	36

#	ARTICLE	IF	CITATIONS
19	Genetic correlates of socio-economic status influence the pattern of shared heritability across mental health traits. <i>Nature Human Behaviour</i> , 2021, 5, 1065-1073.	6.2	41
20	Explaining the Differences in Opioid Overdose Deaths between Scotland and England/Wales: Implications for European Opioid Policies. <i>European Addiction Research</i> , 2021, 27, 399-412.	1.3	23
21	Effect of Methylphenidate on Resting-State Connectivity in Adolescents With a Disruptive Behavior Disorder: A Double-Blind Randomized Placebo-Controlled fMRI Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 662652.	1.3	2
22	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention Deficit Hyperactivity Disorder and Substance Use Disorder. <i>Çocuk Ve Genişlik Ruh Sağılığı Dergisi / Turkish Journal of Child and Adolescent Mental Health</i> , 2021, 28, 79-88.	0.2	0
23	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1722-1734.	1.4	12
24	The effect of N-acetylcysteine and working memory training on glutamate concentrations in the dACC and rACC in regular cocaine users – A randomized proof of concept study. <i>Neuroscience Letters</i> , 2021, 762, 136146.	1.0	2
25	Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. <i>Neurotoxicity Research</i> , 2021, 39, 2120-2133.	1.3	12
26	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 789-818.	2.9	483
27	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108984.	1.6	12
28	Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. <i>European Neuropsychopharmacology</i> , 2021, 52, 18-30.	0.3	13
29	Potential influence of socioeconomic status on genetic correlations between alcohol consumption measures and mental health. <i>Psychological Medicine</i> , 2020, 50, 484-498.	2.7	44
30	A Comparison of Excessive Drinking, Binge Drinking and Alcohol Dependence in Ethnic Minority Groups in the Netherlands: The HELIUS Study. <i>European Addiction Research</i> , 2020, 26, 66-76.	1.3	4
31	Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial. <i>Addiction</i> , 2020, 115, 917-923.	1.7	8
32	Post-GWAS analysis of six substance use traits improves the identification and functional interpretation of genetic risk loci. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107703.	1.6	19
33	Safety of nalmefene for the treatment of alcohol use disorder: an update. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 9-17.	1.0	3
34	Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial. <i>Addictive Behaviors</i> , 2020, 103, 106228.	1.7	12
35	Onset and Severity of Early Disruptive Behavioral Disorders in Treatment-Seeking Substance Use Disorder Patients with and without Attention-Deficit/Hyperactivity Disorder. <i>European Addiction Research</i> , 2020, 26, 211-222.	1.3	4
36	Further evidence for the association of <i>GAL</i> , <i>GALR1</i> and <i>NPY1R</i> variants with opioid dependence. <i>Pharmacogenomics</i> , 2020, 21, 903-917.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Demographic and Clinical Characteristics of Regular GHB-Users with and without GHB-Induced Comas. <i>Substance Use and Misuse</i> , 2020, 55, 2148-2155.	0.7	6
38	Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders. <i>European Addiction Research</i> , 2020, 26, 191-200.	1.3	8
39	Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders. <i>European Addiction Research</i> , 2020, 26, 201-210.	1.3	11
40	Contribution of Alcohol and Nicotine Dependence to the Prevalence of Depressed Mood in Different Ethnic Groups in The Netherlands: The HELIUS Study. <i>Journal of Dual Diagnosis</i> , 2020, 16, 271-284.	0.7	4
41	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2020, , .	1.0	6
42	Tackling rising numbers of opioid prescriptions users. <i>Lancet Public Health</i> , The, 2020, 5, e139.	4.7	2
43	Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders. <i>Journal of Dual Diagnosis</i> , 2020, 16, 208-217.	0.7	10
44	Effects of Recreational GHB Use and Multiple GHB-Induced Comas on Brain Structure and Impulsivity. <i>Frontiers in Psychiatry</i> , 2020, 11, 166.	1.3	8
45	A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. <i>Addiction</i> , 2019, 114, 1095-1109.	1.7	160
46	Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. <i>Lancet Public Health</i> , The, 2019, 4, e498-e505.	4.7	134
47	The Unhealthy Chicken or the Unhealthy Egg: Quitting Smoking Matters: Response to Hajek et al.. <i>American Journal of Psychiatry</i> , 2019, 176, 575-576.	4.0	0
48	High-potency cannabis and incident psychosis: correcting the causal assumption. <i>Lancet Psychiatry</i> ,the, 2019, 6, 464-465.	3.7	5
49	The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Emotion Processing, Reappraisal, and Craving in Alcohol Use Disorder Patients and Healthy Controls: A Functional Magnetic Resonance Imaging Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 272.	1.3	22
50	Emotion Processing, Reappraisal, and Craving in Alcohol Dependence: A Functional Magnetic Resonance Imaging Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 227.	1.3	17
51	VMAT2 gene (<i>SLC18A2</i>) variants associated with a greater risk for developing opioid dependence. <i>Pharmacogenomics</i> , 2019, 20, 331-341.	0.6	8
52	Influence of Gamma-Hydroxybutyric Acid-Use and Gamma-Hydroxybutyric Acid-Induced Coma on Affect and the Affective Network. <i>European Addiction Research</i> , 2019, 25, 173-181.	1.3	7
53	Defining Compulsive Behavior. <i>Neuropsychology Review</i> , 2019, 29, 4-13.	2.5	64
54	The effect of N-acetylcysteine and working memory training on neural mechanisms of working memory and cue reactivity in regular cocaine users. <i>Psychiatry Research - Neuroimaging</i> , 2019, 287, 56-59.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. <i>Neuroscience Letters</i> , 2019, 704, 100-105.	1.0	5
56	Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial. <i>Drug and Alcohol Dependence</i> , 2019, 197, 28-36.	1.6	32
57	Recreational use of GHB is associated with alterations of resting state functional connectivity of the central executive and default mode networks. <i>Human Brain Mapping</i> , 2019, 40, 2413-2421.	1.9	13
58	Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder. <i>Current Opinion in Psychiatry</i> , 2019, 32, 300-306.	3.1	12
59	Use of the Fagerstr�m test to assess differences in the degree of nicotine dependence in smokers from five ethnic groups: The HELIUS study. <i>Drug and Alcohol Dependence</i> , 2019, 194, 197-204.	1.6	10
60	Self�wise, Other�wise, Streetwise (SOS) training, an intervention to prevent victimization in dual�diagnosis patients: results from a randomized clinical trial. <i>Addiction</i> , 2019, 114, 730-740.	1.7	12
61	Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 25-34.	3.7	30
62	International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. <i>European Addiction Research</i> , 2018, 24, 43-51.	1.3	108
63	Reprint of The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. <i>Addictive Behaviors</i> , 2018, 83, 79-86.	1.7	6
64	Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. <i>Pharmacogenomics</i> , 2018, 19, 95-104.	0.6	15
65	Factors associated with victimization in dual diagnosis patients. <i>Journal of Substance Abuse Treatment</i> , 2018, 84, 68-77.	1.5	14
66	Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. <i>Schizophrenia Research</i> , 2018, 194, 32-38.	1.1	20
67	Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. <i>Journal of Psychopharmacology</i> , 2018, 32, 353-356.	2.0	13
68	Differential Effects of Left and Right Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation on Resting-State Functional Magnetic Resonance Imaging in Healthy Individuals. <i>Brain Connectivity</i> , 2018, 8, 60-67.	0.8	19
69	The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. <i>Addictive Behaviors</i> , 2018, 79, 24-31.	1.7	23
70	Causal Factors of Increased Smoking in ADHD: A Systematic Review. <i>Substance Use and Misuse</i> , 2018, 53, 432-445.	0.7	42
71	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018, 5, 957-960.	3.7	94
72	Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. <i>Harm Reduction Journal</i> , 2018, 15, 47.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Effect of GHB-use and GHB-induced comas on dorsolateral prefrontal cortex functioning in humans. <i>NeuroImage: Clinical</i> , 2018, 20, 923-930.	1.4	12
74	The use and helpfulness of self-management strategies for depression: The experiences of patients. <i>PLoS ONE</i> , 2018, 13, e0206262.	1.1	22
75	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 94-101.	1.6	10
76	Adverse effects of GHB-induced coma on long-term memory and related brain function. <i>Drug and Alcohol Dependence</i> , 2018, 190, 29-36.	1.6	19
77	Enhanced Amygdala-Striatal Functional Connectivity during the Processing of Cocaine Cues in Male Cocaine Users with a History of Childhood Trauma. <i>Frontiers in Psychiatry</i> , 2018, 9, 70.	1.3	15
78	Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. <i>American Journal of Psychiatry</i> , 2018, 175, 1121-1128.	4.0	49
79	Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. <i>Addiction Biology</i> , 2018, 23, 969-986.	1.4	59
80	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	1.9	20
81	Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. <i>Annals of Internal Medicine</i> , 2018, 169, 732.	2.0	116
82	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
83	Neurobiology of ADHD and comorbid substance use disorders. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY18-3.	0.0	0
84	White matter alterations in cocaine users are negatively related to the number of additionally (ab)used substances. <i>Addiction Biology</i> , 2017, 22, 1048-1056.	1.4	35
85	Loss of brain graph network efficiency in alcohol dependence. <i>Addiction Biology</i> , 2017, 22, 523-534.	1.4	55
86	A new nomenclature for classifying psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1614-1616.	1.1	26
87	Response to "Baclofen and alcohol use disorders: From miracle to mirage". <i>European Neuropsychopharmacology</i> , 2017, 27, 693-694.	0.3	1
88	ICD-11 Gaming Disorder: Needed and just in time or dangerous and "much too early?". <i>Journal of Behavioral Addictions</i> , 2017, 6, 290-292.	1.9	44
89	Diagnosing ADHD during active substance use: Feasible or flawed?. <i>Drug and Alcohol Dependence</i> , 2017, 180, 371-375.	1.6	18
90	Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. <i>Drug and Alcohol Dependence</i> , 2017, 179, 117-123.	1.6	20

#	ARTICLE	IF	CITATIONS
91	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. <i>American Journal of Public Health</i> , 2017, 107, e1-e12.	1.5	295
92	Design of a syndemic based intervention to facilitate care for men who have sex with men with high risk behaviour: the syn.bas.in randomized controlled trial. <i>BMC Infectious Diseases</i> , 2017, 17, 398.	1.3	13
93	Childhood trauma exposure in substance use disorder patients with and without ADHD. <i>Addictive Behaviors</i> , 2017, 65, 118-124.	1.7	26
94	The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials. <i>European Neuropsychopharmacology</i> , 2017, 27, 82-86.	0.3	14
95	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. <i>PLoS Medicine</i> , 2017, 14, e1002396.	3.9	362
96	Doubt in the Insula: Risk Processing in Obsessive-Compulsive Disorder. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 283.	1.0	15
97	The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. <i>Drug and Alcohol Dependence</i> , 2016, 163, 48-54.	1.6	20
98	Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2016, 164, 55-63.	1.6	8
99	Hyperresponsiveness of the Neural Fear Network During Fear Conditioning and Extinction Learning in Male Cocaine Users. <i>American Journal of Psychiatry</i> , 2016, 173, 1033-1042.	4.0	13
100	Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. <i>Drug and Alcohol Dependence</i> , 2016, 168, 164-169.	1.6	14
101	Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. <i>Substance Use and Misuse</i> , 2016, 51, 1905-1911.	0.7	11
102	Reactivity to social stress in ethnic minority men. <i>Psychiatry Research</i> , 2016, 246, 629-636.	1.7	11
103	Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. <i>European Neuropsychopharmacology</i> , 2016, 26, 1941-1949.	0.3	77
104	Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. <i>European Neuropsychopharmacology</i> , 2016, 26, 1950-1959.	0.3	118
105	Treatment Seeking for Alcohol Use Disorders: Treatment Gap or Adequate Self-Selection?. <i>European Addiction Research</i> , 2016, 22, 277-285.	1.3	50
106	Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 616-626.	2.0	20
107	Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016, 387, 2226-2234.	6.3	65
108	Compulsivity in obsessive-compulsive disorder and addictions. <i>European Neuropsychopharmacology</i> , 2016, 26, 856-868.	0.3	183

#	ARTICLE	IF	CITATIONS
109	Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. PLoS ONE, 2016, 11, e0152482.	1.1	62
110	Early Nonresponse in the Antipsychotic Treatment of Acute Mania. Journal of Clinical Psychiatry, 2016, 77, e1117-e1123.	1.1	5
111	Persistence and desistance in heavy cannabis use: the role of identity, agency, and life events. Journal of Youth Studies, 2015, 18, 617-633.	1.5	27
112	Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods.. Health Psychology, 2015, 34, 677-685.	1.3	52
113	Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. Human Brain Mapping, 2015, 36, 4222-4230.	1.9	22
114	A guide on gene prioritization in studies of psychiatric disorders. International Journal of Methods in Psychiatric Research, 2015, 24, 245-256.	1.1	6
115	Self-reported cue-induced physical symptoms of craving as an indicator of cocaine dependence. American Journal on Addictions, 2015, 24, 740-743.	1.3	11
116	The Misuse of Prescription Opioids: A Threat for Europe?. Current Drug Abuse Reviews, 2015, 8, 3-14.	3.4	180
117	Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology, 2015, 29, 678-687.	2.0	18
118	Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. British Journal of Psychiatry, 2015, 207, 5-14.	1.7	191
119	Resting state connectivity in alcohol dependent patients and the effect of repetitive transcranial magnetic stimulation. European Neuropsychopharmacology, 2015, 25, 2230-2239.	0.3	46
120	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion on Drug Safety, 2015, 14, 495-504.	1.0	18
121	Integrated cognitive behavioral therapy for patients with Substance Use Disorder and Comorbid ADHD: Two case presentations. Addictive Behaviors, 2015, 45, 214-217.	1.7	18
122	Incentive Processing in Persistent Disruptive Behavior and Psychopathic Traits: A Functional Magnetic Resonance Imaging Study in Adolescents. Biological Psychiatry, 2015, 78, 615-624.	0.7	63
123	Brain function during cognitive flexibility and white matter integrity in alcohol-dependent patients, problematic drinkers and healthy controls. Addiction Biology, 2015, 20, 979-989.	1.4	31
124	The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology, 2015, 29, 254-263.	2.0	211
125	The role of leisure and delinquency in frequent cannabis use and dependence trajectories among young adults. International Journal of Drug Policy, 2015, 26, 143-152.	1.6	11
126	Near-fatal persistent anion- and osmolal-gap acidosis due to massive gamma-butyrolactone/ethanol intoxication. Annals of Clinical Biochemistry, 2015, 52, 283-287.	0.8	7

#	ARTICLE	IF	CITATIONS
127	Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 197-206.	1.4	21
128	European rating of drug harms. <i>Journal of Psychopharmacology</i> , 2015, 29, 655-660.	2.0	153
129	Prevalence and construct validity of compulsive buying disorder in shopping mall visitors. <i>Psychiatry Research</i> , 2015, 228, 918-924.	1.7	42
130	Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults. <i>Drug and Alcohol Review</i> , 2015, 34, 683-693.	1.1	47
131	Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. <i>Journal of Psychopharmacology</i> , 2015, 29, 344-348.	2.0	3
132	Ranking the harm of non-medically used prescription opioids in the UK. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 999-1004.	1.3	17
133	Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. <i>International Journal of Drug Policy</i> , 2015, 26, 1177-1182.	1.6	35
134	Recreational nitrous oxide use: Prevalence and risks. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 790-796.	1.3	163
135	Early developmental, temperamental and educational problems in "substance use disorder" patients with and without ADHD. Does ADHD make a difference?. <i>Addictive Behaviors Reports</i> , 2015, 2, 13-18.	1.0	4
136	Impact of DSM-5 Changes on the Diagnosis and Acute Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 637-643.	2.3	24
137	Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. <i>Addictive Behaviors</i> , 2015, 40, 91-95.	1.7	59
138	Cue Reactivity Is Associated with Duration and Severity of Alcohol Dependence: An fMRI Study. <i>PLoS ONE</i> , 2014, 9, e84560.	1.1	58
139	Wim van den Brink and colleagues reply to Des Spence and Alain Braillon. <i>BMJ</i> , The, 2014, 348, g2605-g2605.	3.0	4
140	The Role of Habits and Motivation in Human Drug Addiction: A Reflection. <i>Frontiers in Psychiatry</i> , 2014, 5, 8.	1.3	29
141	Reduced Frontal Brain Volume in Non-Treatment-Seeking Cocaine-Dependent Individuals: Exploring the Role of Impulsivity, Depression, and Smoking. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 7.	1.0	36
142	Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 70, 507-513.	1.3	19
143	Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. <i>Journal of Psychopharmacology</i> , 2014, 28, 733-744.	2.0	109
144	Increased Release of Dopamine in the Striata of Young Adults With Hearing Impairment and Its Relevance for the Social Defeat Hypothesis of Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1364.	6.0	52

#	ARTICLE	IF	CITATIONS
145	Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia – An individual patient data meta-analysis. <i>European Neuropsychopharmacology</i> , 2014, 24, 1067-1077.	0.3	10
146	Alcohol consumption and symptoms as predictors for relapse of DSM-5 alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2014, 140, 85-91.	1.6	43
147	Relationship between trait impulsivity and cortical volume, thickness and surface area in male cocaine users and non-drug using controls. <i>Drug and Alcohol Dependence</i> , 2014, 144, 210-217.	1.6	33
148	Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. <i>Drug and Alcohol Dependence</i> , 2014, 144, 70-77.	1.6	33
149	Enhanced striatal responses during expectancy coding in alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2014, 142, 204-208.	1.6	27
150	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. <i>Drug and Alcohol Dependence</i> , 2014, 145, 101-105.	1.6	29
151	Guideline for Screening, Diagnosis and Treatment of ADHD in Adults with Substance Use Disorders. <i>International Journal of Mental Health and Addiction</i> , 2014, 12, 629-647.	4.4	8
152	The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. <i>Journal of Psychopharmacology</i> , 2014, 28, 633-642.	2.0	22
153	Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. <i>Clinical Psychology Review</i> , 2014, 34, 531-550.	6.0	109
154	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. <i>Drug and Alcohol Dependence</i> , 2014, 134, 158-166.	1.6	150
155	Dimensions and disorder specificity of impulsivity in pathological gambling. <i>Addictive Behaviors</i> , 2014, 39, 1646-1651.	1.7	73
156	Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. <i>British Journal of Psychiatry</i> , 2014, 204, 486-487.	1.7	10
157	Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands. <i>Drug and Alcohol Dependence</i> , 2014, 138, 177-184.	1.6	32
158	Treatment Outcome of Alcohol Use Disorder Outpatients With or Without Medically Assisted Detoxification. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 993-998.	0.6	4
159	Does Self-medication Predict the Persistence or Rather the Recurrence of Alcohol Dependence?. <i>JAMA Psychiatry</i> , 2014, 71, 205.	6.0	1
160	Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: A randomized placebo-controlled cross-over study using pharmacological fMRI. <i>Addictive Behaviors</i> , 2013, 38, 1509-1517.	1.7	47
161	Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. <i>Alcohol and Alcoholism</i> , 2013, 48, 570-578.	0.9	293
162	A randomised controlled trial of outpatient versus inpatient integrated treatment of dual diagnosis patients: a failed but informative study. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2012, 5, 132-147.	0.5	3

#	ARTICLE	IF	CITATIONS
163	Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity. <i>Addictive Behaviors</i> , 2011, 36, 570-575.	1.7	19
164	Heroin-assisted treatment in the Netherlands: History, findings, and international context. <i>European Neuropsychopharmacology</i> , 2010, 20, S105-S158.	0.3	53
165	Psychosocial work conditions and work stress in an innovating addiction treatment centre. Consequences for the EFQM Excellence Model. <i>Total Quality Management and Business Excellence</i> , 2009, 20, 267-281.	2.4	20
166	THE SDSS SCALE—A REPLY TO GONZÁLEZ-SÁIZ. <i>Addiction</i> , 2007, 102, 828-829.	1.7	0
167	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. <i>Journal of Urban Health</i> , 2007, 84, 552-562.	1.8	107
168	Evidence-Based Treatment of Opioid-Dependent Patients. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 635-646.	0.9	119
169	Pharmacokinetics and Pharmacokinetic Variability of Heroin and its Metabolites: Review of the Literature. <i>Current Clinical Pharmacology</i> , 2006, 1, 109-118.	0.2	160
170	Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2005, 80, 283-295.	1.6	31
171	Science-based practice for methadone treatment: another step forward. <i>International Journal of Public Health</i> , 2003, 48, S15-6; discussion S25-7.	2.7	0
172	Pharmacological treatments for heroin and cocaine addiction. <i>European Neuropsychopharmacology</i> , 2003, 13, 476-487.	0.3	69
173	Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2003, 327, 310-0.	2.4	278
174	The relationship between socio-economic inequality and criminal victimisation: a prospective study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2001, 36, 361-370.	1.6	18
175	Consequences of the use of different classification systems: a comparison of the DSM-III-R and the ICD-10 for depression. <i>International Journal of Methods in Psychiatric Research</i> , 1999, 8, 192-203.	1.1	1
176	Survival in a population-based cohort of dementia patients: predictors and causes of mortality. , 1999, 14, 748-753.		33